Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

G. Attard; J. Clark; L. Ambroisine; I. G. Mills; G. Fisher; P. Flohr; A. Reid; S. Edwards; G. Kovacs; D. Berney; C. Foster; C. E. Massie; A. Fletcher; J. S. De Bono; P. Scardino; J. Cuzick; C. S. Cooper

doi:10.1038/sj.bjc.6604472

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

G. Attard, J. Clark, L. Ambroisine, I. G. Mills, G. Fisher, P. Flohr, A. Reid, S. Edwards, G. Kovacs, D. Berney, C. Foster, C. E. Massie, A. Fletcher, J. S. De Bono, P. Scardino, J. Cuzick, C. S. Cooper

Research output: Contribution to journal › Article › peer-review

90 Citations (Scopus)

Abstract

A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5′-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5′-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.

Original language	English
Pages (from-to)	314-320
Number of pages	7
Journal	British Journal of Cancer
Volume	99
Issue number	2
DOIs	https://doi.org/10.1038/sj.bjc.6604472
Publication status	Published - 1 Jul 2008

Keywords

ACSL3
ACSL3:ETV1 fusion
ETV1
Prostate cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.bjc.6604472

Cite this

Attard, G., Clark, J., Ambroisine, L., Mills, I. G., Fisher, G., Flohr, P., Reid, A., Edwards, S., Kovacs, G., Berney, D., Foster, C., Massie, C. E., Fletcher, A., De Bono, J. S., Scardino, P., Cuzick, J., & Cooper, C. S. (2008). Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. British Journal of Cancer, 99(2), 314-320. https://doi.org/10.1038/sj.bjc.6604472

@article{3bfcfd9f7389487bb7113f637ec9d57c,

title = "Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer",

abstract = "A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5′-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5′-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.",

keywords = "ACSL3, ACSL3:ETV1 fusion, ETV1, Prostate cancer",

author = "G. Attard and J. Clark and L. Ambroisine and Mills, {I. G.} and G. Fisher and P. Flohr and A. Reid and S. Edwards and G. Kovacs and D. Berney and C. Foster and Massie, {C. E.} and A. Fletcher and {De Bono}, {J. S.} and P. Scardino and J. Cuzick and Cooper, {C. S.}",

note = "Funding Information: This work was funded by Cancer Research UK, the National Cancer Research Institute, National Institutes of Health (SPORE) the Grand Charity of Freemasons, The Rosetrees Trust, The Orchid Appeal and the Koch Foundation. Funding bodies had no involvement in the design and conduct of the study, or in collection management, analysis and interpretation of the data, or in preparation, review or approval of the paper. We thank Christine Bell for help with typing the paper.",

year = "2008",

month = jul,

day = "1",

doi = "10.1038/sj.bjc.6604472",

language = "English",

volume = "99",

pages = "314--320",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

Attard, G, Clark, J, Ambroisine, L, Mills, IG, Fisher, G, Flohr, P, Reid, A, Edwards, S, Kovacs, G, Berney, D, Foster, C, Massie, CE, Fletcher, A, De Bono, JS, Scardino, P, Cuzick, J & Cooper, CS 2008, 'Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer', British Journal of Cancer, vol. 99, no. 2, pp. 314-320. https://doi.org/10.1038/sj.bjc.6604472

TY - JOUR

T1 - Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

AU - Attard, G.

AU - Clark, J.

AU - Ambroisine, L.

AU - Mills, I. G.

AU - Fisher, G.

AU - Flohr, P.

AU - Reid, A.

AU - Edwards, S.

AU - Kovacs, G.

AU - Berney, D.

AU - Foster, C.

AU - Massie, C. E.

AU - Fletcher, A.

AU - De Bono, J. S.

AU - Scardino, P.

AU - Cuzick, J.

AU - Cooper, C. S.

N1 - Funding Information: This work was funded by Cancer Research UK, the National Cancer Research Institute, National Institutes of Health (SPORE) the Grand Charity of Freemasons, The Rosetrees Trust, The Orchid Appeal and the Koch Foundation. Funding bodies had no involvement in the design and conduct of the study, or in collection management, analysis and interpretation of the data, or in preparation, review or approval of the paper. We thank Christine Bell for help with typing the paper.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5′-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5′-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.

AB - A fluorescence in situ hybridisation (FISH) assay has been used to screen for ETV1 gene rearrangements in a cohort of 429 prostate cancers from patients who had been diagnosed by trans-urethral resection of the prostate. The presence of ETV1 gene alterations (found in 23 cases, 5.4%) was correlated with higher Gleason Score (P=0.001), PSA level at diagnosis (P=<0.0001) and clinical stage (P=0.017) but was not linked to poorer survival. We found that the six previously characterised translocation partners of ETV1 only accounted for 34% of ETV1 re-arrangements (eight out of 23) in this series, with fusion to the androgen-repressed gene C15orf21 representing the commonest event (four out of 23). In 5′-RACE experiments on RNA extracted from formalin-fixed tissue we identified the androgen-upregulated gene ACSL3 as a new 5′-translocation partner of ETV1. These studies report a novel fusion partner for ETV1 and highlight the considerable heterogeneity of ETV1 gene rearrangements in human prostate cancer.

KW - ACSL3

KW - ACSL3:ETV1 fusion

KW - ETV1

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=48249150750&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6604472

DO - 10.1038/sj.bjc.6604472

M3 - Article

C2 - 18594527

AN - SCOPUS:48249150750

VL - 99

SP - 314

EP - 320

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Cite this